| Autor: |
Prabhu VV; a Oncoceutics, Inc. , Philadelphia , PA., Talekar MK; b The Children's Hospital of Philadelphia , Philadelphia , PA., Lulla AR; c Fox Chase Cancer Center , Philadelphia , PA., Kline CLB; c Fox Chase Cancer Center , Philadelphia , PA., Zhou L; c Fox Chase Cancer Center , Philadelphia , PA., Hall J; b The Children's Hospital of Philadelphia , Philadelphia , PA., Van den Heuvel APJ; d Penn State College of Medicine , Hershey , PA., Dicker DT; c Fox Chase Cancer Center , Philadelphia , PA., Babar J; c Fox Chase Cancer Center , Philadelphia , PA., Grupp SA; b The Children's Hospital of Philadelphia , Philadelphia , PA., Garnett MJ; e Wellcome Trust Sanger Institute , Hinxton , UK., McDermott U; e Wellcome Trust Sanger Institute , Hinxton , UK., Benes CH; f Massachusetts General Hospital, Harvard Medical School , Boston , MA., Pu JJ; d Penn State College of Medicine , Hershey , PA., Claxton DF; d Penn State College of Medicine , Hershey , PA., Khan N; c Fox Chase Cancer Center , Philadelphia , PA., Oster W; a Oncoceutics, Inc. , Philadelphia , PA., Allen JE; a Oncoceutics, Inc. , Philadelphia , PA., El-Deiry WS; a Oncoceutics, Inc. , Philadelphia , PA. |
| Abstrakt: |
ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1-8 µM) dose- and time-dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples. ONC201 induced caspase-dependent apoptosis that involved activation of the integrated stress response (ATF4/CHOP) pathway, inhibition of Akt phosphorylation, Foxo3a activation, downregulation of cyclin D1, IAP and Bcl-2 family members. ONC201 synergistically reduced cell viability in combination with cytarabine and 5-azacytidine in AML cells. ONC201 combined with cytarabine in a Burkitt's lymphoma xenograft model induced tumor growth inhibition that was superior to either agent alone. ONC201 synergistically combined with bortezomib in MM, MCL and ALCL cells and with ixazomib or dexamethasone in MM cells. ONC201 combined with bortezomib in a Burkitt's lymphoma xenograft model reduced tumor cell density and improved CHOP induction compared to either agent alone. These results serve as a rationale for ONC201 single-agent trials in relapsed/refractory acute leukemia, non-Hodgkin's lymphoma, MM and combination trial with dexamethasone in MM, provide pharmacodynamic biomarkers and identify further synergistic combinatorial regimens that can be explored in the clinic. |
